Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

Dr. Wangjian Zhong

Hematology Oncology | Hematology | Oncology
Baptist Health Medical Group Inc
4002 Kresge Way, Suite 110, 
Louisville, KY 
Accepting New Patients
Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Baptist Health Medical Group Inc
4002 Kresge Way, Suite 110, 
Louisville, KY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Wangjian Zhong is a Hematologist Oncology specialist and a Hematologist in Louisville, Kentucky. Dr. Zhong is rated as an Experienced provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). His top areas of expertise are Childhood Iron Deficiency Anemia, Lung Cancer, Anal Cancer, and Thrombocytopenia. Dr. Zhong is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in KY
Hospital Affiliations
Baptist Health Lagrange
Baptist Health Hardin
Baptist Health Louisville
Languages Spoken
English
Mandarin
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

BAPTIST HEALTH MEDICAL GROUP INC
4002 Kresge Way, Suite 110, Louisville, KY 40207
Other Locations
BAPTIST HEALTH MEDICAL GROUP INC
2400 Eastpoint Pkwy, Louisville, KY 40223
BAPTIST HEALTH MEDICAL GROUP INC
1025 New Moody Ln, La Grange, KY 40031
BAPTIST HEALTH MEDICAL GROUP INC
4003 Kresge Way, Louisville, KY 40207

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug
Study Drugs: N-803+Pembrolizumab, N-803+Carboplatin+Nab-paclitaxel+Pembrolizumab, N-803+Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed, Pembrolizumab, Carboplatin+Nab-paclitaxel or Paclitaxel+Pembrolizumab, Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed
Study Phase: Phase 3
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Drug
Study Drugs: N-803, Pembrolizumab, Nivolumab, Atezolizumab, Avelumab, Durvalumab, PD-L1 t-haNK
Study Phase: Phase 2
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: August 26, 2025
Intervention Type: Drug
Study Drugs: Zimberelimab, Domvanalimab, Etrumadenant
Study Phase: Phase 2
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 04, 2025
Intervention Type: Drug
Study Drugs: Itacitinib, Osimertinib
Study Phase: Phase 1/Phase 2
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Veliparib
Study Phase: Phase 2
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2025
Intervention Type: Drug, Other
Study Drug: Adjuvant Chemotherapy
Study Phase: Not Applicable
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Biological, Drug
Study Drugs: Viagenpumatucel-L, Nivolumab, Pembrolizumab, Pemetrexed
Study Phase: Phase 1/Phase 2
The Circulating Cell-free Genome Atlas Study
The Circulating Cell-free Genome Atlas Study
Enrollment Status: Unknown
Publish Date: September 13, 2023
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: September 01, 2022
Intervention Type: Other
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: February 03, 2021
Intervention Type: Other
View 11 Less Clinical Trials

1 Total Publications

Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial.
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial.
Journal: The Lancet. Respiratory medicine
Published: May 06, 2025
Similar Doctors
Advanced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Udaya G. Joseph
Hematology Oncology | Hematology | Oncology
Advanced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Udaya G. Joseph
Hematology Oncology | Hematology | Oncology

Baptist Health Medical Group Inc

4003 Kresge Way, Suite 500, 
Louisville, KY 
 (0.2 miles away)
502-897-1166
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Udaya Joseph is a Hematologist Oncology specialist and a Hematologist in Louisville, Kentucky. Dr. Joseph is rated as a Distinguished provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Myelodysplastic Syndrome (MDS), and Inflammatory Breast Cancer. Dr. Joseph is currently accepting new patients.

Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Ignacio Montes
Hematology Oncology | Hematology | Oncology
Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Ignacio Montes
Hematology Oncology | Hematology | Oncology
4003 Kresge Way, Ste 500, 
Louisville, KY 
 (0.2 miles away)
502-897-1166
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Ignacio Montes is a Hematologist Oncology specialist and a Hematologist in Louisville, Kentucky. Dr. Montes is rated as a Distinguished provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). His top areas of expertise are Opitz G BBB Syndrome, Thrombocytopenia, Chronic Lymphocytic Leukemia (CLL), Paget Disease of the Breast, and Bone Marrow Aspiration. Dr. Montes is currently accepting new patients.

Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Don A. Stevens
Oncology
Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Don A. Stevens
Oncology

Norton Hospitals Inc

3991 Dutchmans Ln, Suite 405, 
Louisville, KY 
 (0.3 miles away)
502-899-2673
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Don Stevens is an Oncologist in Louisville, Kentucky. Dr. Stevens is rated as an Elite provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). His top areas of expertise are Non-Hodgkin Lymphoma, Multiple Myeloma, Follicular Lymphoma, Bone Marrow Aspiration, and Ureteroscopy. Dr. Stevens is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zhong's expertise for a condition
ConditionClose
    View All 12 Distinguished Conditions
    View All 50 Advanced Conditions
    View All 169 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile